Technician assembling a medical device in a cleanroom
The Indian government is preparing to enact a new legislation that will replace the colonial-era Drugs and Cosmetics Act of 1940. This comprehensive overhaul aims to modernize the regulatory framework for drugs, medical devices, and cosmetics, aligning it with contemporary industry standards and global best practices.
Key provisions of the forthcoming law include strengthening the powers of the Drugs Controller General of India (DCGI), the national drug regulator. The new legislation is expected to introduce stricter penalties and bail conditions for serious offenses related to drug manufacturing and distribution, thereby enhancing compliance and deterring illicit activities.
Furthermore, the proposed law is designed to facilitate faster approval processes for new drugs and medical devices, while also enabling more efficient product recalls when necessary. A significant aspect of the reform is the establishment of dedicated regulatory and advisory bodies specifically for medical devices, acknowledging the sector’s rapid growth and unique challenges.
This legislative update is anticipated to foster greater trust in India’s pharmaceutical and medical device markets, potentially attracting more investment and improving the overall quality and safety of healthcare products available to the public.
About the Author
